AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34184057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 32021087 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ng/kg/min AM via continuous 12-h intravenous infusion
Number of subjects: 36
Study 32021087 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 ng/kg/min AM via continuous 12-h intravenous infusion
Number of subjects: 36
Study 32021087 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ng/kg/min AM via continuous 12-h intravenous infusion
Number of subjects: 36
Study 32021087 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ng/kg/min AM for 8 h per day for 7 days
Number of subjects: 36
Study 32021087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 34617277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (3 mg/kg, Ketofen 10%, Ceva Animal Health)
Number of subjects: 158
Study 34617277 — intervention group
Group type: COMPARATOR
Intervention: Control (topical application of oxytetracycline spray only)
Number of subjects: 158
Study 32345356 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin measured at 24 hours
Number of subjects: 690
Study 35780725 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid plus methylprednisolone
Number of subjects: 262
Study 35780725 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid alone
Number of subjects: 262
Study 35780725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 35780725 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid with or without methylprednisolone
Number of subjects: 262
Study 32938325 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization Group (SG)
Number of subjects: 40
Study 32938325 — intervention group
Group type: EXPERIMENTAL
Intervention: Superstabilization Group (SSG)
Number of subjects: 40
Study 33724373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 223
Study 33724373 — intervention group
Group type: COMPARATOR
Intervention: Control arm (tenofovir disoproxil fumarate/emtricitabine with a third agent)
Number of subjects: 223
Study 33261981 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-frequency (RF) adenoid ablation
Number of subjects: 80
Study 33261981 — intervention group
Group type: COMPARATOR
Intervention: Curettage group
Number of subjects: 80
Study 32080085 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic naso-gallbladder drainage (ENGBD)
Number of subjects: 0
Study 32080085 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transhepatic gallbladder drainage (PTGBD)
Number of subjects: 0
Study 35238406 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception group (consultant as a subject)
Number of subjects: 44
Study 35238406 — intervention group
Group type: COMPARATOR
Intervention: Non-deception group (consultant acting a part)
Number of subjects: 44
Study 35135967 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb for 3-7 days
Number of subjects: 50
Study 35135967 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 50
Study 33711221 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percent increase
Number of subjects: 2160
Study 33711221 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk fat percent increase
Number of subjects: 2160
Study 32239210 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed TARGIT‐IORT
Number of subjects: 1153
Study 32239210 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 1153
Study 35922124 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 0
Study 35922124 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 0
Study 35922124 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 0
Study 33249580 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB) 120 mg
Number of subjects: 2886
Study 33249580 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB) 240 mg
Number of subjects: 2886
Study 33249580 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB)
Number of subjects: 2886
Study 33249580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2886
Study 35508860 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention at bilateral Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39), Tianshu (ST 25), and Zhongwan (RN 12) acupoints, 30 min per time, twice daily, for 7 days
Number of subjects: 500
Study 35508860 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention
Number of subjects: 500
Study 33455137 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (monosialotetrahexose ganglioside sodium + conventional rehabilitation)
Number of subjects: 144
Study 33455137 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment group (conventional rehabilitation)
Number of subjects: 144
Study 33455137 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 144
Study 32045314 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 0
Study 34051142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 208
Study 34051142 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin
Number of subjects: 208
Study 33020204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (initial dose of 400 mg/m2 IV followed by weekly doses of 250 mg/m2, one cycle = 4 weeks)
Number of subjects: 30
Study 33020204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 30
Study 34647301 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 386
Study 34647301 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 386
Study 33464580 — intervention group
Group type: EXPERIMENTAL
Intervention: Besa 2.0
Number of subjects: 81
Study 33464580 — intervention group
Group type: EXPERIMENTAL
Intervention: Encevis 1.7
Number of subjects: 81
Study 33464580 — intervention group
Group type: EXPERIMENTAL
Intervention: Persyst 13
Number of subjects: 81
Study 34571095 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan (120 mg MR)
Number of subjects: 15
Study 34571095 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg)
Number of subjects: 15
Study 34571095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 34817600 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (24 experts)
Number of subjects: 52
Study 34817600 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (28 experts)
Number of subjects: 52
Study 34817600 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-group analysis
Number of subjects: 52
Study 34817600 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel-group analysis
Number of subjects: 52
Study 33287865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT) for 12 months
Number of subjects: 302
Study 33287865 — intervention group
Group type: COMPARATOR
Intervention: Standard probation as usual (Control)
Number of subjects: 302
Study 33287865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 302
Study 33406997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA) at 0° deviation
Number of subjects: 15
Study 33406997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA) at 15° deviation
Number of subjects: 15
Study 33406997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA) at 30° deviation
Number of subjects: 15
Study 33406997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual prism adaptation (PA)
Number of subjects: 15
Study 33406997 — intervention group
Group type: COMPARATOR
Intervention: Control (wedge prisms)
Number of subjects: 15
Study 33789243 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5 mg·kg‐1 body mass
Number of subjects: 12
Study 33789243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 12
Study 32781992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ranitidine (3 mg/kg/day) for 10 days
Number of subjects: 40
Study 32781992 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (5 to 10 billion CFUs of Lactobacillus rhamnosus) for 10 days
Number of subjects: 40
Study 32781992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mg of oral vitamin C tablet) for 10 days
Number of subjects: 40
Study 36210273 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse incubator
Number of subjects: 1224
Study 36210273 — intervention group
Group type: COMPARATOR
Intervention: Standard incubator
Number of subjects: 1224
Study 33839918 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (AMP)
Number of subjects: 459
Study 33839918 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial prophylaxis (no AMP)
Number of subjects: 459
Study 32170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature birth
Number of subjects: 154
Study 32170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 154
Study 32170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural states (quiet and awake)
Number of subjects: 154
Study 32170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural states (active and asleep)
Number of subjects: 154
Study 32170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural states (quiet and asleep)
Number of subjects: 154
Study 32170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 154
Study 32170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of the heel stick procedure
Number of subjects: 154
Study 35859277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP ≤ 130 mmHg)
Number of subjects: 3176
Study 35859277 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP ≤ 140 mmHg)
Number of subjects: 3176
Study 34646359 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe extract (n = 38)
Number of subjects: 213
Study 34646359 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (n = 33)
Number of subjects: 213
Study 32964514 — intervention group
Group type: EXPERIMENTAL
Intervention: Study treatment
Number of subjects: 0
Study 32964514 — intervention group
Group type: COMPARATOR
Intervention: External control group
Number of subjects: 0
Study 34042953 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological VNN (BioVNN)
Number of subjects: 0
Study 34042953 — intervention group
Group type: COMPARATOR
Intervention: Traditional neural networks
Number of subjects: 0
Study 34042953 — intervention group
Group type: COMPARATOR
Intervention: Neural network based on randomized pathways
Number of subjects: 0
Study 32883104 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-hours admission
Number of subjects: 686
Study 32883104 — intervention group
Group type: COMPARATOR
Intervention: OFF-hours admission
Number of subjects: 686
Study 32883104 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 686
Study 32883104 — intervention group
Group type: COMPARATOR
Intervention: Immediate multivessel PCI
Number of subjects: 686
Study 33724391 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bupivacaine
Number of subjects: 280
Study 33724391 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 280
Study 33724391 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 280
Study 32801102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL) 1200 mg once daily (QD)
Number of subjects: 547
Study 32801102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL) 800 mg once daily (QD)
Number of subjects: 547
Study 32801102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 32801102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL)
Number of subjects: 547
Study 33864234 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 68
Study 33864234 — intervention group
Group type: COMPARATOR
Intervention: Continued Behavioral Weight-Loss Treatment (Control)
Number of subjects: 68
Study 33864234 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Weight-Related Experiential Avoidance (AAQW-R)
Number of subjects: 68
Study 33864234 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Treatment Weight-Related Experiential Avoidance (AAQW-R)
Number of subjects: 68
Study 33742664 — intervention group
Group type: EXPERIMENTAL
Intervention: Precommitment intervention (upfront voluntary choice restriction)
Number of subjects: 83
Study 33742664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no precommitment)
Number of subjects: 83
Study 33742664 — intervention group
Group type: EXPERIMENTAL
Intervention: Precommitment intervention
Number of subjects: 83
Study 33742664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 33742664 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on self-directed cognitive training
Number of subjects: 83
Study 32799787 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic donor nephrectomy
Number of subjects: 75
Study 34878953 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440 mg (NapS)
Number of subjects: 212
Study 34878953 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone plus acetaminophen 10/650 mg (HYD+APAP)
Number of subjects: 212
Study 34878953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 32798172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Pecto-intercostal fascial block with 0.25% bupivacaine
Number of subjects: 80
Study 32798172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36058564 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone taper (MPT) course following surgery
Number of subjects: 56
Study 36058564 — intervention group
Group type: COMPARATOR
Intervention: Control group (preoperative dexamethasone only)
Number of subjects: 56
Study 32829027 — intervention group
Group type: EXPERIMENTAL
Intervention: CLS-TA plus intravitreal aflibercept (active group)
Number of subjects: 71
Study 32829027 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept monotherapy (control group)
Number of subjects: 71
Study 32915843 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation cohort (n = 1,273)
Number of subjects: 4139
Study 32915843 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n = 636)
Number of subjects: 4139
Study 32915843 — intervention group
Group type: EXPERIMENTAL
Intervention: Japan-CTO extension score
Number of subjects: 4139
Study 35798710 — intervention group
Group type: EXPERIMENTAL
Intervention: Compacted dual-head power toothbrush (DH)
Number of subjects: 24
Study 35798710 — intervention group
Group type: COMPARATOR
Intervention: Single-head power toothbrush (SH)
Number of subjects: 24
Study 35798710 — intervention group
Group type: EXPERIMENTAL
Intervention: Compacted dual-head power toothbrush (DH) for 45 seconds
Number of subjects: 24
Study 34135055 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and Vitamin D supplementation
Number of subjects: 504
Study 34135055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 32718550 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for thromboembolic events
Number of subjects: 72381
Study 32718550 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for MACE
Number of subjects: 72381
Study 32718550 — intervention group
Group type: COMPARATOR
Intervention: CHADS2 risk model
Number of subjects: 72381
Study 32718550 — intervention group
Group type: COMPARATOR
Intervention: CHA2DS2-VASc risk model
Number of subjects: 72381
Study 35166687 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterLife smartphone app for 10 weeks
Number of subjects: 126
Study 35166687 — intervention group
Group type: COMPARATOR
Intervention: Control group on waiting list for 10 weeks
Number of subjects: 126
Study 34852781 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol and remifentanil)
Number of subjects: 80
Study 34852781 — intervention group
Group type: COMPARATOR
Intervention: SEVO (sevoflurane and remifentanil)
Number of subjects: 80
Study 32314841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing and standard ventilation
Number of subjects: 40
Study 32314841 — intervention group
Group type: EXPERIMENTAL
Intervention: No pacing and HFJV
Number of subjects: 40
Study 32314841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing and HFJV
Number of subjects: 40
Study 32314841 — intervention group
Group type: COMPARATOR
Intervention: No pacing and standard ventilation
Number of subjects: 40
Study 32314841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing and HFJV together
Number of subjects: 40
Study 35346048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dopamine infusion
Number of subjects: 294
Study 35346048 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative norepinephrine use
Number of subjects: 294
Study 32643361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoadsorption (CytoSorb®)
Number of subjects: 15
Study 32436160 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate lozenges
Number of subjects: 80
Study 32436160 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate tablets
Number of subjects: 80
Study 32436160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablets or lozenges)
Number of subjects: 80
Study 36471322 — intervention group
Group type: COMPARATOR
Intervention: High Degree of Implementation (DOI)
Number of subjects: 476
Study 36471322 — intervention group
Group type: COMPARATOR
Intervention: Low Degree of Implementation (DOI)
Number of subjects: 476
Study 33839618 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone
Number of subjects: 307
Study 35887695 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 54
Study 35887695 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) 1000 mg
Number of subjects: 54
Study 35887695 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) 2000 mg
Number of subjects: 54
Study 32970554 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 self‐triage website
Number of subjects: 877
Study 35561333 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stoves
Number of subjects: 1205
Study 35561333 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved chimney stove
Number of subjects: 1205
Study 35561333 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional solid fuel (TSF) stoves with built-in chimney
Number of subjects: 1205
Study 35561333 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitchen chimneys
Number of subjects: 1205
Study 35561333 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional solid fuel without improved technology)
Number of subjects: 1205
Study 33526618 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib + MTX
Number of subjects: 739
Study 33526618 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib monotherapy
Number of subjects: 739
Study 32139286 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension band wiring (TBW)
Number of subjects: 20
Study 32139286 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation (PF) with locking screws
Number of subjects: 20
Study 32139286 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TBW and PF
Number of subjects: 20
Study 32139286 — intervention group
Group type: EXPERIMENTAL
Intervention: Construct stiffness measurement
Number of subjects: 20
Study 32139286 — intervention group
Group type: COMPARATOR
Intervention: Cyclic test
Number of subjects: 20
Study 32139286 — intervention group
Group type: COMPARATOR
Intervention: Load-to-failure test
Number of subjects: 20
Study 34338105 — intervention group
Group type: EXPERIMENTAL
Intervention: The Pause (intervention group)
Number of subjects: 0
Study 34338105 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33089364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (5% inspired CO2, +7 mmHg PETCO2) during LBNP
Number of subjects: 12
Study 33089364 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (room air) during LBNP
Number of subjects: 12
Study 32867959 — intervention group
Group type: EXPERIMENTAL
Intervention: QCT-generated bone mineral content (BMC) analysis
Number of subjects: 125
Study 32867959 — intervention group
Group type: EXPERIMENTAL
Intervention: QCT BMC vs actual ash weight comparison
Number of subjects: 125
Study 36209129 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Spikevax®)
Number of subjects: 600
Study 36209129 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 (Comirnaty®)
Number of subjects: 600
Study 34064438 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoception group (n = 31)
Number of subjects: 61
Study 34064438 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 61
Study 34551895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led follow-up via telehealth including serum CA125 monitoring and completion of the MOST-S26
Number of subjects: 150
Study 34551895 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic based follow-up
Number of subjects: 150
Study 32209529 — intervention group
Group type: EXPERIMENTAL
Intervention: iHOPE programme
Number of subjects: 114
Study 34124817 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to MAA‐LDL
Number of subjects: 423
Study 34124817 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to heat shock protein 60 of Aggregatibacter actinomycetemcomitans
Number of subjects: 423
Study 34124817 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary IgA antibodies to Porphyromonas gingivalis
Number of subjects: 423